Kenneth Hoberman

Board Director

Director

US·SEC (Form 4)

TG Therapeutics, Inc.Nuvectis Pharma, Inc.Stemline Therapeutics Inc

Total declarations

Companies

▲ Purchases (1 ops.)

€101k

▼ Sales (0 ops.)

—

Latest filing published 16 Jun 2025 for TG Therapeutics, INC.. Read the official filing

Filing timeline

BuySale

Kenneth Hoberman

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

T+90 mean return

-42.0%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Kenneth Hoberman: trading record in brief

This profile gathers the share dealings of Kenneth Hoberman across 3 companies, led by TG Therapeutics, Inc., Nuvectis Pharma, Inc. and Stemline Therapeutics Inc. Between 7 January 2016 and 12 June 2025, the trades on record add up to 10 filings.

Purchases make up the whole of the open-market record (1 purchase, €101k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 9 share grants.

The newest entry dates from 16 June 2025: a share grant, in TG Therapeutics, Inc. The most recent open-market purchase was published on 16 May 2022, 1,616 days ago. Typically, a trade is published a median of 4 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.